befol
a reverse inhibitor of monoaminoxidase; exhibits selective action on serotonin deamination; RN given refers to parent cpd
Also Known As:
4-chloro-N-(3-morpholinopropyl)benzamide; LIS 630; LIS-630; befol monohydrochloride
Networked: 7
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Related Diseases
1. | Hypoxia (Hypoxemia)
|
2. | Cardiac Arrhythmias (Arrythmia)
12/01/1997
- " [Cardiotoxic effect of the anti-arrhythmia preparation rhythmidazole and its correction with sufan, befol and their combination]." 09/01/1993
- " [New pharmacodynamic effects of gidazepam and befol in patients with cardiac arrhythmias]." 12/01/1996
- " [Comparative anti-arrhythmia activity of befol, lidocaine, and bonnecor]." 09/01/1993
- " The new Russian drugs gidazepam, a tranquilizer, and befol, an antidepressant, show not only their psychotropic action, but change cardiac electrophysiological function and produce antiarrhythmic effects, which allows them to be used in the treatment of various cardiac arrhythmias. " 05/01/1998
- " [Anti-arrhythmia activity of befol, sufan, mexidol, and T3-146 in combination with other anti-arrhythmia agents]."
|
3. | Ventricular Premature Complexes (Premature Ventricular Contraction)
|
4. | Paroxysmal Tachycardia
|
5. | Dystonia (Limb Dystonia)
|
|
Related Drugs and Biologics